Difficulty: Medium
Average Score: 79%
Practice
The substance binding to one receptor subtype as an agonist and to another as an antagonist is called:
Correct answer
C
Rationale
In pharmacology, understanding the concept of a substance binding to different receptor subtypes is crucial for effective medication management. The correct answer to the question is C) Agonist-antagonist. This term describes a substance that can act as an agonist at one type of receptor while simultaneously acting as an antagonist at another type of receptor. This dual action is particularly relevant in the context of drugs that have mixed effects on different receptor subtypes.
Competitive antagonist (A) refers to a substance that competes with an agonist for binding to a receptor, thereby blocking the agonist's effects. Irreversible antagonist (B) irreversibly binds to a receptor, rendering it unavailable for agonist binding. Partial agonist (D) is a substance that activates a receptor but produces a submaximal response compared to a full agonist.
In a clinical setting, understanding the concept of a substance binding to different receptor subtypes can guide healthcare providers in predicting the effects of a drug and managing potential interactions. This knowledge is particularly relevant when selecting medications for patients with complex conditions that may benefit from drugs with dual agonist-antagonist actions.
Competitive antagonist (A) refers to a substance that competes with an agonist for binding to a receptor, thereby blocking the agonist's effects. Irreversible antagonist (B) irreversibly binds to a receptor, rendering it unavailable for agonist binding. Partial agonist (D) is a substance that activates a receptor but produces a submaximal response compared to a full agonist.
In a clinical setting, understanding the concept of a substance binding to different receptor subtypes can guide healthcare providers in predicting the effects of a drug and managing potential interactions. This knowledge is particularly relevant when selecting medications for patients with complex conditions that may benefit from drugs with dual agonist-antagonist actions.